[1]姚远方,高 飞,张雪松,等.载药微球加载贝伐珠单抗介入栓塞治疗兔VX2肝癌的抗血管生成效果[J].介入放射学杂志,2021,30(03):254-257.
 YAO Yuanfang,GAO Fei,ZHANG Xuesong,et al.The anti-angiogenesis effect of interventional embolization using drug-loaded microspheres with bevacizumab in treating rabbit VX2 hepatocellular carcinoma[J].journal interventional radiology,2021,30(03):254-257.
点击复制

载药微球加载贝伐珠单抗介入栓塞治疗兔VX2肝癌的抗血管生成效果()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
30
期数:
2021年03
页码:
254-257
栏目:
实验研究
出版日期:
2021-03-29

文章信息/Info

Title:
The anti-angiogenesis effect of interventional embolization using drug-loaded microspheres with bevacizumab in treating rabbit VX2 hepatocellular carcinoma
作者:
姚远方 高 飞 张雪松 王魁阳 隋成旭 张 亮 吴 杰 宋 磊
Author(s):
YAO Yuanfang GAO Fei ZHANG Xuesong WANG Kuiyang SUI Chengxu ZHANG Liang WU Jie SONG Lei.
Department of Intervention, Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province 116027, China
关键词:
【关键词】 载药微球 贝伐珠单抗 经导管动脉化疗栓塞术 兔VX2肝癌模型 血管内皮细胞生长因子
文献标志码:
A
摘要:
【摘要】 目的 探讨载药微球加载贝伐珠单抗经导管动脉化疗栓塞(TACE)治疗兔VX2 肝癌模型的抗血管生成效果。方法 构建30只新西兰大白兔VX2 肝癌模型,随机分为HepaSphere载药微球加载贝伐珠单抗组(A组,n=10)、Embosphere微球联合贝伐珠单抗组(B组,n=10)、单纯HepaSphere载药微球组(C组,n=10)。酶联免疫吸附试验(ELISA)法定量检测TACE术前1 d,术后1、7、14 d各组血清血管内皮细胞生长因子(VEGF)水平,术前1 d、术后14 d腹部MRI检测各组肿瘤直径,计算瘤体体积和肿瘤增长率。结果 术后 7 d A组、B组血清VEGF水平与C组相比均较低(P<0.05),且A组低于B组;术后14 d 3组血清VEGF水平两两比较差异均有统计学意义(P<0.05),A组最低,C组最高。术后14 d 3组肿瘤增长率两两比较差异均有统计学意义(P<0.05),A组最低。结论 载药微球加载贝伐珠单抗TACE治疗可明显降低兔VX2 肝癌模型术后血清VEGF水平和肿瘤增长率,疗效优于单纯载药微球或栓塞微球联合贝伐珠单抗治疗。

参考文献/References:

[1] Daher S, Massarwa M, Benson AA, et al. Current and future treatment of hepatocellular carcinoma: an updated comprehensive review[J]. J Clin Transl Hepatol, 2018, 6: 69- 78.
[2] Tanigawa T, Hasuike Y, Akiyama Y, et al. Pre- operative treatment with transcatheter arterial chemoembolization(TACE) and hepatic arterial infusion(HAI) for liver metastasis from gastric cancer: a case report[J]. Gan To Kagaku Ryoho, 2015, 42: 1460- 1462.
[3] 徐国辉,徐宗全,周 峥,等. TACE 联合贝伐珠单抗治疗不可切除结直肠癌肝转移的临床研究[J]. 实用癌症杂志, 2015, 30:1493- 1497.
[4] 李静娴,姜艳萍,王家平,等. 葡聚糖微球联合多西紫杉醇介入治疗原发性肝癌的临床疗效[J].实用放射学杂志, 2017, 33:739- 741.
[5] 刘 嵘,王建华,周康荣,等. 不同介入方法治疗兔VX- 2肝肿瘤的实验研究[J]. 实用放射学杂志, 2001, 17:561- 564.
[6] 杨 奎,尹 君,靳雪广,等. 不同介入模式治疗肝癌的比较研究[J]. 临床放射学杂志, 2006, 25:658- 662.
[7] 陈 卫,邓 俊,杨小娟,等. 肝癌双灌注介入治疗后血清TNF- α、sIL- 2R以及VEGF水平的变化与预后相关[J]. 临床肝胆病杂志, 2010, 26:203- 204.
[8] 兰 涛,周国庆,王桂华. 血管内皮生长因子与肝癌[J]. 中国中西医结合外科杂志, 2014, 20:212- 214.
[9] 万 健,唐才喜,冯 斌,等. 原发性肝癌中Numb和VEGF的表达及临床意义[J]. 中国普通外科杂志, 2015, 24:39- 44.
[10] 张明明,李 娜,邹长鹏,等. 抗血管生成药物治疗晚期肝癌的应用进展[J]. 河北医药, 2014, 36:1064- 1067.
[11] 管清龙,纪卫政,任伟新,等. 肝癌介入治疗后血清缺氧诱导因子和血管内皮生长因子含量变化对预后的影响[J]. 介入放射学杂志, 2014, 23:142- 146.
[12] 贾中芝,冯耀良,施海彬. 原发性肝癌TACE前后血清HIF- 1α与VEGF的相关性[J]. 中国介入影像与治疗学, 2010, 7:117- 120.
[13] Li Z, Xue TQ, Chen XY. Predictive values of serum VEGF and CRP levels combined with contrast enhanced MRI in hepatocel- lular carcinoma patients after TACE[J]. Am J Cancer Res, 2016, 6: 2375- 2385.
[14] Gupta S, Wright KC, Ensor J, et al. Hepatic arterial embolization with doxorubicin- loaded superabsorbent polymer microspheres in a rabbit liver tumor model[J]. Cardiovasc Intervent Radiol, 2011, 34: 1021- 1030.
[15] 金雪锋,陈庆财,宗在伟,等. 载药肝动脉栓塞微球的发展现状[J]. 中国新药杂志, 2013, 22:2268- 2273.
[16] Hiraki T, Koizumi J, Arai Y, et al. Transcatheter arterial embo- lization of hypervascular tumors with HepaSphere: prospective multicenter open label clinical trial of microspheres in Japan[J]. Jpn J Radiol, 2015, 33: 479- 486.
[17] 周振兴,宋军民,陈姬华,等. 贝伐珠单抗在肿瘤治疗中的应用研究进展[J]. 药学进展, 2015, 39:525- 532.
[18] Britten CD, Gomes AS, Wainberg ZA, et al. Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study[J]. BMC Cancer, 2012, 12: 16.
[19] 于 奇,吴 杰,高 飞,等. 载药微球加载贝伐珠单抗治疗难治性实体瘤4例[J]. 介入放射学杂志, 2019, 28:81- 84.
[20] Zhou J, Tang ZY, Fan J, et al. Expression of platelet- derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus[J]. J Cancer Res Clin Oncol, 2000, 126: 57- 61.

相似文献/References:

[1]王辅明,刘敬禹,杨继金.载药微球治疗腹膜后平滑肌肉瘤术后肝转移1例 [J].介入放射学杂志,2018,27(04):308.
 WANG Fuming,LIU Jingyu,YANG Jijin.Drug- eluting beads for the treatment of hepatic metastasis following surgery of retroperitioneal leiomyosarcoma: report of one case[J].journal interventional radiology,2018,27(03):308.
[2]于 奇,吴 杰,高 飞,等.载药微球加载贝伐珠单抗治疗难治性实体瘤4例[J].介入放射学杂志,2019,28(01):81.
 YU Qi,WU Jie,GAO Fei,et al.HepaSphere loaded with bevacizumab for the treatment of refractory solid tumors: preliminary results in 4 patients[J].journal interventional radiology,2019,28(03):81.
[3]纪坤,李臻,李鑫,等.载药微球化疗栓塞治疗巨大扁桃体鳞癌1例 [J].介入放射学杂志,2020,29(02):219.
 JI Kun,LI Zhen,LI Xin,et al.Successful treatment of giant tonsillar squamous cell carcinoma with chemoembolization by using drug-eluting beads: report of one case[J].journal interventional radiology,2020,29(03):219.
[4]李 梅,宋娟荣,翟鹏涛,等.载药微球在原发性肝癌TACE治疗中疗效及安全性分析[J].介入放射学杂志,2021,30(02):186.
 LI Mei,SONG Juanrong,ZHAI Pengtao,et al.Transcatheter arterial chemoembolization with drug-eluting beads in the treatment of primary hepatocellular carcinoma: analysis of its curative effect and safety[J].journal interventional radiology,2021,30(03):186.

备注/Memo

备注/Memo:
(收稿日期:2020- 02- 25)
(本文编辑:边 佶)
更新日期/Last Update: 2021-03-25